SUSTAINABILITY REPORT 2013-15

People Overview Self Managed Teams Mechanisation Safety Overview The Parivartan     Journey Progress on     Roadmap Incident Statistics Robust Governance Standardised     Processes Enhanced Awareness Capability Building Safety Infrastructure Safety Audits Quality Overview Top-down    Accountability Quality by Design Quality Culture     Transformation Quality Assurance Quality     Best Practices All Time Audit     Readiness Availability Overview Strategic Sourcing Risk Management Product    Rationalisation Success stories Environment Overview Roadmap Energy Management Emissions Water Waste Case Study KPIs Community Overview Focus Areas Education Livelihoods Healthcare Infrastructure     Initiatives Creating Change     Makers Productivity Overview Productivity Streams Case Study PACE Update Initiatives Engineering Excellence Overview Digitisation Automation Mechanisation Lean Manufacturing Capital Equipment Strategy Predictive Maintenance Continuous Improvement Overview Continuous     Improvement     at Work Best Practices Annexures GRI Index Acronyms Assurance Statement   Summary Report     ECONOMIC PERFORMANCE AFFORDABLE & INNOVATIVE MEDICINE Overview    |    AIM Timelines    |    Global Generics    |    PSAI    |    Proprietary Products Overview Accelerating Access In his 2001 address to the World Health Assembly, UN Secretary General Kofi Annan said, “The biggest enemy of health in the developing world is poverty.” It is rather unfortunate that those who are more prone to fall ill, are the same ones who can ill afford the medicines. With increasing average life span and decreasing government support, even the well-off are feeling the heat, when unwell. The three basic tenets that help operationalise our vision are: Affordability     Accessibility     Availability   These are actualised by our three core businesses: Global Generics To enable people to lead healthier lives by making medicines affordable, our Global Generics segment which includes branded and unbranded prescriptions as well as over-the-counter (OTC) drugs, offers lower cost alternatives to highly priced innovator brands, either directly or through collaborations.     PSAI To enable people to lead healthier lives by making medicines accessible, our PSAI segment leverages our strengths to offer technology-advantaged products, niche product service capabilities, technology platforms and competitive cost structures to in-house manufacturing divisions, as well as other pharma companies, to enable faster launches of affordable and innovative products.     Proprietary Products To enable people to lead healthier lives by making innovative medicines available, our Proprietary Products segment works on three different models. New Chemical Entities (NCEs): The discovery and development of new small molecule agents in various therapeutic areas. Specialty Business: In-licensed patented dermatology products and off-patent cardiovascular products. Differentiated Formulations: New, synergistic combinations and technologies that improve safety and/or efficacy by modifying the pharmacokinetics of existing medicines.